Moleculin Biotech
MBRX
18 hedge funds and large institutions have $2.28M invested in Moleculin Biotech in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 8 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
0% less ownership
Funds ownership: 0% → 0% (-0%)
25% less funds holding
Funds holding: 24 → 18 (-6)
39% less capital invested
Capital invested by funds: $3.71M → $2.28M (-$1.44M)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$278K |
| 2 |
Millennium Management
New York
|
+$198K |
| 3 |
ECM
ETrade Capital Management
Arlington,
Virginia
|
+$55.3K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
+$34K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$14.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$869K |
| 2 |
Renaissance Technologies
New York
|
-$451K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$34K |
| 4 |
HWA
HCR Wealth Advisors
Los Angeles,
California
|
-$14K |
| 5 |
Squarepoint
New York
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Squarepoint
New York
| – | -$11K | -5 | Closed |
|
|
PAG
27
Private Advisor Group
Morristown,
New Jersey
| – | -$5K | -2 | Closed |
|
|
CAN
28
Cetera Advisor Networks
El Segundo,
California
| – | -$2K | -1 | Closed |
|
|
OPS
29
Orion Portfolio Solutions
Omaha,
Nebraska
| – | -$3K | -1 | Closed |
|
|
TFS
30
TrustCore Financial Services
Brentwood,
Tennessee
| – | -$2K | -1 | Closed |
|
MBRX Hedge Fund Activity: Q3 2020 in Review
18 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2020, worth a combined $2.28M — down 39% from $3.71M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MBRX and 2 opened new positions — a net loss of 6 holders — while 2 trimmed existing stakes and 8 added.
The largest buyer was Qube Research & Technologies (QRT), adding an estimated $278K. The largest seller was Vanguard Group, cutting an estimated $869K.
- 18 institutional investors held Moleculin Biotech (MBRX) as of Q3 2020, down from 24 in Q2 2020.
- Funds reported $2.28M of Moleculin Biotech stock for Q3 2020, down 39% quarter-over-quarter.
- 2 funds opened new Moleculin Biotech positions in Q3 2020 and 8 closed out, a net change of -6 holders.
- The largest Moleculin Biotech buyer in Q3 2020 was Qube Research & Technologies (QRT), an estimated $278K added.
- The largest Moleculin Biotech seller in Q3 2020 was Vanguard Group, an estimated $869K sold.
Based on aggregated 13F filings for Q3 2020.